Cargando…

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes

OBJECTIVE: This randomized, controlled noninferiority trial aimed to compare the efficacy and safety of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) (both with prandial insulin aspart) in pregnant women with type 1 diabetes. RESEARCH DESIGN AND METHODS: Patients were randomized and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathiesen, Elisabeth R., Hod, Moshe, Ivanisevic, Marina, Duran Garcia, Santiago, Brøndsted, Lise, Jovanovič, Lois, Damm, Peter, McCance, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447831/ https://www.ncbi.nlm.nih.gov/pubmed/22851598 http://dx.doi.org/10.2337/dc11-2264

Ejemplares similares

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
por: Hod, Moshe, et al.
Publicado: (2014)

Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study
por: Mathiesen, Elisabeth R., et al.
Publicado: (2021)

Hypoglycemia in Type 1 Diabetic Pregnancy: Role of preconception insulin aspart treatment in a randomized study
por: Heller, Simon, et al.
Publicado: (2010)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
por: Strandberg, Arto Y., et al.
Publicado: (2016)

Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin
por: Begg, Denovan P., et al.
Publicado: (2015)

Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins
por: Mathiesen, Elisabeth R., et al.
Publicado: (2017)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)
por: Wheeler, Mark D., et al.
Publicado: (2018)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Effects of Insulin Detemir and NPH Insulin on Body Weight and Appetite-Regulating Brain Regions in Human Type 1 Diabetes: A Randomized Controlled Trial
por: van Golen, Larissa W., et al.
Publicado: (2014)

Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA(1c) and spikes of high glucose values in the third trimester
por: Damm, Peter, et al.
Publicado: (2014)

Comparison of treatment with insulin detemir and NPH in women with gestational diabetes mellitus: glycemic control and pregnancy outcomes. A retrospective study
por: Kazakou, Paraskevi, et al.
Publicado: (2023)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
por: Rys, Przemyslaw, et al.
Publicado: (2015)

Insulin Requirements in Type 1 Diabetic Pregnancy: Do twin pregnant women require twice as much insulin as singleton pregnant women?
por: Callesen, Nicoline F., et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
por: Morales, Cristóbal, et al.
Publicado: (2015)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Cerebral Blood Flow and Glucose Metabolism in Appetite-Related Brain Regions in Type 1 Diabetic Patients After Treatment With Insulin Detemir and NPH Insulin: A randomized controlled crossover trial
por: van Golen, Larissa W., et al.
Publicado: (2013)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Comparison of Insulin Lispro Protamine Suspension with NPH Insulin in Pregnant Women with Type 2 and Gestational Diabetes Mellitus: Maternal and Perinatal Outcomes
por: Colatrella, Antonietta, et al.
Publicado: (2013)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
por: Philips, Jean-Christophe, et al.
Publicado: (2006)

Cerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir
por: Tschritter, Otto, et al.
Publicado: (2007)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander, Priscilla A
Publicado: (2012)

Insulin Detemir in Pregnancy: A Small but Significant Step Forward?
por: McElduff, Aidan
Publicado: (2012)

The role of insulin detemir in overweight type 2 diabetes management
por: Demssie, Yared N, et al.
Publicado: (2009)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study
por: Lucidi, Paola, et al.
Publicado: (2011)

Study of a New Modified Insulin (Type N.P.H.)
por: Mukherjee, Surath Kumar
Publicado: (1952)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
por: Sartorius, Tina, et al.
Publicado: (2016)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
por: Zafar, Mohammad Ishraq, et al.
Publicado: (2014)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Abstract 6: Maternal efficacy, safety, and pregnancy outcomes with degludec versus detemir in the treatment of pregnant women with type 1 diabetes: An international, multicentre, randomised trial
por: Balaji, Kamaleswari, et al.
Publicado: (2022)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012)

All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK
por: Husemoen, Lise Lotte Nystrup, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d3pe49apgqf8t10vj9s4d3vrar